risk of glp 1 for weight loss GLP-1 drugs leave users low on key nutrients, study finds GLP1 Weight Loss Risk in

Tirzepatide: Also known as LY3298176, Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist

Ann Pharmacother (2017) 51(5):4019

What to Expect and When Weeks 46 Reduced shedding and less scalp irritation

By contrast, a recent clinical trial by Eli Lilly tracked nearly 400 subjects who switched from shots to Foundayo, and found that on average, they maintained most of their weight loss after 52 weeks

This fixed-dose combination emerged from recognition that targeting complementary pathways GLP-1 receptors through GLP1 and amylin-calcitonin receptors through cagrilintide could produce synergistic metabolic benefits exceeding either agent alone

Thanks for any advice